Clinical Trials & Medical Discoveries The most recent news and results from scientific and medical research, covering all aspects of healthcare, including testing, diagnosis, and treatment. Stay up-to-date on the latest medical discoveries and breakthroughs with announcements of new products to be tested, upcoming clinical trials and studies, and newly published results. Also included are updates regarding funding decisions, company performance, and legal news.

Latest

08:31 ET BioMarin Announces New England Journal of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up to 42 Months in Children with Achondroplasia

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that the New England Journal of Medicine (NEJM) published online today results from a Phase 2...


08:30 ET Medicenna Presents Preliminary Top-Line Clinical Results from their Phase 2b Trial of MDNA55 in Recurrent Glioblastoma

-Disease control rate of up to 83% achieved; evidence of improved survival for patients TORONTO and HOUSTON, June 18, 2019 /PRNewswire/ - Medicenna...


08:10 ET Menarini Silicon Biosystems Introduces Use of DEPArray System for Challenging Flow Cytometry Applications at CYTO Congress

Menarini Silicon Biosystems, the pioneer of liquid biopsy and single cell technologies, will introduce its latest developments of the DEPArray™...


08:00 ET Daiichi Sankyo's VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory FLT3-ITD AML

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the Ministry of Health, Labor and Welfare (MHLW) of Japan has...


08:00 ET Groundbreaking Tikun Olam Research Study Confirms Cannabis Effectively Treats Fibromyalgia, Decreases Pharmaceutical & Opioid Use

Patients suffering from fibromyalgia experience significant improvement in pain, sleep, and depression symptoms after treatment with Tikun Olam...


08:00 ET FDA Grants Fast Track Designation for Torque's First Deep-Primed T Cell Cancer Immunotherapy Program, TRQ-1501

Torque, a clinical-stage immuno-oncology company developing Deep-Primed™ T Cell Therapeutics to direct immune power deep within the tumor...


08:00 ET DURECT Announces Completion of the 90 mg Severe Cohort and Dose Escalation Committee Approval to Commence 150 mg Dosing in Patients with Severe Alcoholic Hepatitis (AH) in its Ongoing DUR-928 Phase 2a AH Trial

DURECT Corporation (Nasdaq: DRRX) today announced that it has completed dosing the 90 mg cohort of severe AH patients in its ongoing DUR-928 Phase 2a ...


07:46 ET Breakthrough Device Designation received from the FDA

gel-e Inc., announces Breakthrough Status Designation from the U.S. Food and Drug Administration (FDA) for its first internal-use flowable device....


07:35 ET Kleo Pharmaceuticals Announces a CD38 Targeting Antibody Recruiting Molecule (ARM™) to Treat Multiple Myeloma as the First Clinical Candidate in its Partnership with PeptiDream

Kleo Pharmaceuticals, Inc. (Kleo), an immuno-oncology company developing next-generation synthetic bispecific compounds designed to emulate or...


07:30 ET Atox Bio Announces Exercise by BARDA of Next Option Period to Support Continued Development of Reltecimod for NSTI

Atox Bio, a late stage clinical company developing immunotherapies for critically ill patients, today announced the Biomedical Advanced Research and...


07:00 ET Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...


06:30 ET Patent Covering Manufacturing Process of BiondVax's M-001 Universal Flu Vaccine Allowed in USA and Japan

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), announced today that a patent covering production processes of the Company's M-001 universal influenza...


03:18 ET New Data Demonstrates Impact of Emapalumab in Patients With Macrophage Activation Syndrome (MAS)

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announces that new research demonstrating the effects of emapalumab in patients with macrophage ...


02:16 ET Beactica Wins Grant to Develop Combination Therapy for Glioblastoma

Beactica AB, the Swedish drug discovery company, today announced that it has been awarded a grant of 2.8 MSEK (~$300 000) from SweLife and...


Jun 17, 2019, 20:38 ET Společnost Arena Pharmaceuticals oznámila podání dávky prvnímu subjektu v rámci globálního klinického hodnocení ELEVATE UC 52 fáze 3 vyhodnocujícího přípravek Etrasimod na ulcerózní kolitidu

Společnost Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) dnes oznámila, že byla podána dávka u prvního pacienta v rámci klinického hodnocení ELEVATE UC...


Jun 17, 2019, 20:00 ET Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at 2019 ASCO and EHA Annual Meetings

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines,...


Jun 17, 2019, 15:30 ET Promedior Presents Positive Data from a Phase 2 Study of PRM-151 in Myelofibrosis Patients Failed/Ineligible for Ruxolitinib at the 24th European Hematology Association Annual Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, announced positive safety and...


Jun 17, 2019, 14:43 ET New Data from the RECOVER™ Study Reports on Abstinence, Drug Craving and Psychosocial Outcomes in People with Opioid Use Disorder following Transition from a Clinical Trial to the Real-World Setting

Indivior PLC (LON: INDV) today announced new data from a one-year analysis of the observational RECOVER™ (Remission from Chronic Opioid Use-Studying...


Jun 17, 2019, 14:13 ET Cancer-Sniffing Dogs 97% Accurate in Identifying Lung Cancer, According to Study in The Journal of the American Osteopathic Association

Three beagles successfully showed they are capable of identifying lung cancer by scent, a first step in identifying specific biomarkers for the...


Jun 17, 2019, 11:03 ET Arena Pharmaceuticals annonce le premier sujet à être recruté dans l'essai mondial de phase 3 ELEVATE UC 52 évaluant l'étrasimod dans le traitement de la rectocolite hémorragique

Arena Pharmaceuticals, Inc. (Nasdaq : ARNA) a annoncé aujourd'hui que le premier sujet a été recruté dans ELEVATE UC 52, le premier de deux essais...


Jun 17, 2019, 10:28 ET Zydus Announces Completion of Enrolment in EVIDENCES IV Phase 2 Clinical Trial of Saroglitazar Magnesium in NASH

Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that it has completed enrolment of 104 patients with Non-Alcoholic Fatty ...


Jun 17, 2019, 08:59 ET Immunotherapy Study for Prostate Cancer Active Surveillance Completes Enrollment

Candel Therapeutics (a.k.a. Advantagene, Inc.) announced that it has completed enrollment of the "ULYSSES" trial, a Phase 2 study of ProstAtak® for...


Jun 17, 2019, 08:30 ET Arena Pharmaceuticals meldet Verabreichung an ersten Probanden im Rahmen der Phase-3-Studie ELEVATE UC 52 zur Evaluierung von Etrasimod bei Colitis ulcerosa

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) meldete heute die Verabreichung an den ersten Probanden im Rahmen von ELEVATE UC 52, der ersten von zwei...


Jun 17, 2019, 08:30 ET Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first subject has been dosed in ELEVATE UC 52, the first of two pivotal trials...


Jun 17, 2019, 08:30 ET Arena Pharmaceuticals anuncia al primer paciente del ensayo clínico global fase 3 de ELEVATE UC 52

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ha anunciado hoy que se ha dado tratamiento al primer paciente del ensayo clínico ELEVATE UC 52, el primer ...